Evidence map›Paper›PMID 34545703›Full record

ArticleESC heart failure2021

Phenomapping in patients experiencing worsening renal function during hospitalization for acute heart failure.

Ryuichiro Yagi, Makoto Takei, Shun Kohsaka, Yasuyuki Shiraishi, Nobuhiro Ikemura, Satoshi Shoji, Nozomi Niimi, Satoshi Higuchi, Ayumi Goda, Takashi Kohno and 9 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

Ryuichiro YagiDepartment of Cardiology, Saiseikai Central Hospital, Tokyo, Japan.
Makoto TakeiDepartment of Cardiology, Saiseikai Central Hospital, Tokyo, Japan.
Shun KohsakaDepartment of Cardiology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.
Yasuyuki ShiraishiDepartment of Cardiology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.
Nobuhiro IkemuraDepartment of Cardiology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.
Satoshi ShojiDepartment of Cardiology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.
Nozomi NiimiDepartment of Cardiology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.
Satoshi HiguchiDepartment of Cardiovascular Medicine, Kyorin University Faculty of Medicine, Tokyo, Japan.
Ayumi GodaDepartment of Cardiovascular Medicine, Kyorin University Faculty of Medicine, Tokyo, Japan.
Takashi KohnoDepartment of Cardiovascular Medicine, Kyorin University Faculty of Medicine, Tokyo, Japan.
Yuji NagatomoDepartment of Cardiology, National Defense Medical College, Tokorozawa, Japan.
Yosuke NishihataDepartment of Cardiology, St. Luke's International Hospital, Tokyo, Japan.
Yasumori SujinoDepartment of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan.
Mike SajiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Yukinori IkegamiDepartment of Cardiology, National Defense Medical College, Tokorozawa, Japan.
Shintaro NakanoDepartment of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan.
Toshiyuki TakahashiDepartment of Cardiology, Saiseikai Central Hospital, Tokyo, Japan.
Keiichi FukudaDepartment of Cardiology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.
Tsutomu YoshikawaDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Keio University Hospital · JPKyorin University · JPSaiseikai Central Hospital · JPSakakibara Hospital · JPNational Defense Medical College · JPNational Defense Medical College Hospital · JPSaitama International Medical Center · JPSaitama Medical University · JPSt. Luke's International Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe impact of worsening renal function (WRF) on the prognosis of patients with acute heart failure (AHF) remains controversial. We aimed to identify phenotypically distinct subgroups among individuals with both AHF and WRF using cluster analysis. METHODS AND

resultsOverall, the data of 483 patients with both AHF and WRF enrolled in the West Tokyo Heart Failure Registry were analysed. Using cluster analysis, we identified three phenotypically distinct subgroups (phenogroups 1, 2, and 3). We assessed the impact of WRF on the prognosis of each phenogroup by comparing the incidence of composite endpoints, including all-cause death and re-hospitalization due to heart failure, with those of a propensity score-matched, non-WRF control group. Participants in phenogroup 1 (N = 122) were the youngest (69.3 ± 13.7 years), had relatively preserved estimated glomerular filtration rate (eGFR, 70.0 ± 27.7 mL/min/1.73 m

conclusionsUsing cluster analysis, we revealed three phenotypically distinct subgroups of patients with both AHF and WRF. WRF was associated with worse clinical outcomes in the subgroup of younger patients with reduced LVEF and preserved renal function.

Indexed as

Heart FailureVentricular Function, LeftHospitalizationHumansKidneyStroke VolumeAcute heart failureCardiorenal syndromeCluster analysisDiureticsWorsening renal function

Identifiers

PMID34545703
PMCPMC8712773
OpenAlexW3201032145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.